Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Melanoma 109Lymphoma, T-Cell, Cutaneous 27Mycosis Fungoides 22Skin Neoplasms 20Sezary Syndrome 19Lymphoma, Non-Hodgkin 16Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasm Metastasis 13Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Large-Cell, Anaplastic 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Burkitt Lymphoma 13Hodgkin Disease 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Immunoblastic Lymphadenopathy 11Waldenstrom Macroglobulinemia 10Keratosis, Actinic 10Breast Neoplasms 10Uveal Melanoma 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Myeloid, Acute 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Carcinoma, Basal Cell 9Neoplasms 8

Interventions

veliparib 1Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Non functioning pancreatic endocrine tumor × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡